Corbus Pharmaceuticals Holdings Inc.
Rank 5
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
$43.5600
USD
11.43%
Market cap
$2,816,223,391
Total volume
$34,650,927
Shares outstanding
64,651,593
Rank 5
About
Corbus Pharmaceuticals is a biopharmaceutical company in its third stage of preclinical trials. Their novel therapeutic treatments are aimed at inflammatory and fibrotic conditions. The primary mechanism for these treatments is the endocannabinoid system and the agitation of CB2 receptors. The company operates out of Norwood, Massachusetts.
Markets
Exchange | Symbol | Volume (24h) | Volume (%) | Price |
---|---|---|---|---|
|
CRBP |
$34,650,927
|
100% |
$43.5600
|
Chart